Actinium Pharmaceuticals, Inc
Company Snapshot: Actinium Pharmaceuticals, Inc
Actinium Pharmaceuticals, Inc. (ATNM: NYSE MKT) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium’s targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
- Jun 15 2017 Actinium Pharmaceuticals Announces Appointment of Nitya Ray, Ph.D. as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain and Other Key Hires in its Product Development and Manufacturing Teams
- Jun 15 2017 Actinium Pharmaceuticals Issues Mid-Year Letter to Shareholders Highlighting Accomplishments and Significant Value Enumerating Catalysts Over the Coming Quarters
- Jun 12 2017 Actinium Pharmaceuticals to Host Webinar on June 12th to Update on Pivotal Phase 3 SIERRA Clinical Trial for Iomab-B
- Jun 9 2017 Actinium Pharmaceuticals Announces Appointment of Sandesh Seth as Chief Executive Officer